Thank you for taking time to provide your feedback to the editors. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming ...

It is very difficult to determine the duration of action of 5-HT 3-receptor antagonists at vagal afferent neuronal receptors. A surrogate test that may have clinical relevance is the duration of ...

Knight and Helsinn had entered into an exclusive license, distribution and supply agreement for AKYNZEO ® oral/IV (netupitant/palonosetron / fosnetupitant/palonosetron) in Canada, Brazil, Argentina, ...

As a result of these guidelines, and in an attempt to reduce the overall cost of antiemetic therapy, many institutions have adopted strategies to reduce the total dose of 5-HT3-receptor antagonists.

We knew this going in based on prior studies, but AD04 has also shown higher efficacy among certain patients with certain genetic mutations or genotypes in the 5-HT3 receptor area of the brain. PE: ...

AD04 is designed for patients with specific 5-HT3 receptor mutations (SNPs rs1150226-AG or rs1176713-GG), which may enhance drug binding and efficacy. Adial has developed a Companion Diagnostic ...